07.11.17 Preclinical Results Support Entinostat’s Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy
05.17.17 Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
